We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




Pediatric CKD Progression Linked to Low Serum Bicarbonate

By LabMedica International staff writers
Posted on 02 Jul 2020
Metabolic acidosis is a serious electrolyte disorder characterized by an imbalance in the body's acid-base balance. More...
Metabolic acidosis has three main root causes: increased acid production, loss of bicarbonate, and a reduced ability of the kidneys to excrete excess acids.

Chronic kidney disease (CKD) is a major health problem worldwide. Although relatively uncommon in children, it can be a devastating illness with many long-term consequences. CKD presents unique features in childhood and may be considered, at least in part, as a stand-alone nosologic entity.

Nephrologists at the Children’s National Hospital (Washington, DC, USA) and their colleagues carried out a prospective cohort study of pediatric patients aged 6 months to 16 years with mild to moderate CKD, 603 patients with non-glomerular disease and 255 patients with glomerular disease were included. Patients were analyzed for CKD progression of a 50% decline in baseline eGFR after exposure to serum bicarbonate. Analysis was stratified by glomerular diagnoses and adjusted for alkali therapy utilization.

The scientists reported that at baseline, 39% (237 of 603) of participants with non-glomerular disease had a bicarbonate level of ≤ 22 mEq/L and 36% (85 of 237) of those participants reported alkali therapy treatment. In participants with glomerular disease, 31% (79 of 255) had a bicarbonate of ≤ 22 mEq/L, 18% (14 of 79) of those participants reported alkali therapy treatment. Further adjusted longitudinal analyses compared non-glomerular disease patients with a bicarbonate level of greater than 22 mEq/L, hazard ratios associated with a bicarbonate level of less than 18 mEq/L were calculated at 1.28 and bicarbonate level of less than 19 mEq/L to 22 mEq/L at 0.91. In patients with glomerular disease, adjusted hazard ratios associated with bicarbonate level of at least 18 mEq/L were calculated as 2.16 and bicarbonate of at least 19 mEq/L to 22 mEq/L at 1.74.

Denver D. Brown, MD, a Pediatric Nephrologist and the lead author of the study, said, “Pediatric CKD exacts a large clinical and economic toll. Children with CKD have higher risk for hospitalizations, metabolic abnormalities, cardiovascular disease, growth restriction and cognitive impairment.”

The authors concluded that in children with glomerular disease, low bicarbonate was linked to a higher risk of CKD progression. Resolution of low bicarbonate was associated with a lower risk of CKD progression. Fewer than one half of all children with low bicarbonate reported treatment with alkali therapy. Long-term studies of alkali therapy’s effect in patients with pediatric CKD are needed. The study was published on June 8, 2020 in the Clinical Journal of the American Society of Nephrology.

Related Links:
Children’s National Hospital


New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Serological Pipet Controller
PIPETBOY GENIUS
New
Silver Member
Quality Control Material
Multichem ID-B
New
Clostridium Difficile Toxin A+B Combo Card Test
CerTest Clostridium Difficile Toxin A+B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.